MicroRNAs in androgen-dependent PCa

Frontiers in Bioscience

Volumn 18, Issue 2, 2013, Pages 748-755

  Zhu, Kai Chang ^a,b   Lu, Jia Ju ^a   Xu, Xiao Lin ^b   Sun, Jian Mei ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

MicroRNAs; Prostate cancer; Review; Single Nucleotide Polymorphisms

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; MICRORNA; MIRN125 MICRORNA, HUMAN; MIRN141 MICRORNA, HUMAN; MIRN205 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN;

DISEASE COURSE; GENETICS; HUMAN; MALE; METASTASIS; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

ANDROGENS; DISEASE PROGRESSION; HUMANS; MALE; MICRORNAS; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

MLCS; MLOWN;

EID: 84878779853     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4137     Document Type: Article

References (61)

1. Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D. Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6, e20341 (2011)
2. Hao Y, Zhao Y, Zhao X, He C, Pang X, Wu TC, et al: Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Invest 29, 318-324. (2011)
3. Javidan J, Deitch AD, Shi XB, de Vere White RW. The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Invest 23, 520-8. (2005) (Pubitemid 41463868)
4. Crawford ED, Petrylak D. Castration-resistant prostate cancer: descriptive yet pejorative? J Clin Oncol 28, e408. (2010)
5. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 42(6), 363-369. (2010)
6. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7), 522-531 (2004) (Pubitemid 38868508)
7. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 67(13), 6130-6135. (2007) (Pubitemid 47037493)
8. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101(9), 2999-3004. (2004) (Pubitemid 38327724)
9. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. A polycistronic microRNA cluster, miR- 17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65(21), 9628-9632. (2005) (Pubitemid 41541436)
10. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 435(7043), 828-833. (2005) (Pubitemid 40839734)
11. Li LC. Epigenetics of prostate cancer. Front Biosci 12:3377-97 (2007)
12. Li LC, Okino ST, Dahiya R. DNA methylation in prostate cancer. Biochim Biophys Acta 1704, 87-102. (2004) (Pubitemid 39195351)
13. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68(15), 6162-70. (2008)
14. Sun R, Fu X, Li Y, Xie Y, Mao Y. Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics 10, 93 (2009)
15. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 67(13), 6130-5. (2007)
16. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 147, 798-803. (1992)
17. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, van der Kwast TH. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 39, 927-36 (1991)
18. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer: comparison of receptor content and response to hormonal therapy. Cancer 67, 3057-64. (1991)
19. Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, Velu NK, Bi BY, Chatterjee B. Regulation of androgen action. Vitam. Horm. Vitamins & Hormones 55, 309-52 (1999)
20. Östling P, Leivonen SK, Aakula A, Kohonen P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici D, Bjartell A, Ceder Y, Perälä M, Kallioniemi O. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 71(5), 1956-67 (2011)
21. Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC. miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer 129(4), 810-9 (2011)
22. Xiao J, Gong AY, Eischeid AN, Chen D, Deng C, Young CY, Chen XM. miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate (Epub ahead of print) (2012)
23. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 284(37), 24696-704 (2009)
24. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB. MicroRNA-34 mediates ARdependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 7(8), 1288-96 (2008)
25. Murata T, Takayama K, Katayama S, Urano T, Horie-Inoue K, Ikeda K, Takahashi S, Kawazu C, Hasegawa A, Ouchi Y, Homma Y, Hayashizaki Y, Inoue S. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 13(4), 356-61. (2010)
26. Takayama K, Tsutsumi S, Katayama S, Okayama T, Horie-Inoue K, Ikeda K, Urano T, Kawazu C, Hasegawa A, Ikeo K, Gojyobori T, Ouchi Y, Hayashizaki Y, Aburatani H, Inoue S. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30(5), 619-30. (2011)
27. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White RW. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 104(50), 19983-8 (2007)
28. Rajabi H, Joshi MD, Jin C, Ahmad R, Kufe D. Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. Prostate 71(12), 1299-308 (2011)
29. Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G, Visakorpi T. Androgen regulation of micro-RNAs in prostate cancer. Prostate 71(6), 604-14 (2011)
30. Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, Lei M, Sui G. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 9, 108 (2010)
31. Wang WL, Chatterjee N, Chittur SV, Welsh J, Tenniswood MP. Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer 10, 58 (2011)
32. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69(18), 7165-9. (2009)
33. Ramberg H, Alshbib A, Berge V, Svindland A, Taskén KA. Regulation of PBX3 expression by androgen and Let-7d in prostate cancer. Mol Cancer 10, 50 (2011)
34. Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL. Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer. Hum Mol Genet (Epub ahead of print) (2012)
35. Tang X, Tang X, Gal J, Kyprianou N, Zhu H, Tang G. Detection of microRNAs in prostate cancer cells by microRNA array. Methods Mol Biol 732, 69-88. (2011)
36. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, Valdagni R, Daidone MG, Zaffaroni N. miR-205 exerts tumorsuppressive functions in human prostate through downregulation of protein kinase Cε. Cancer Res 69(6), 2287-95 (2009)
37. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS ONE 5(10), e13500 (2010)
38. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature Clinical Practice Urology 6(2), 76-85. (2009)
39. Attar RM, Takimoto CH, Gottardis MM. Castrationresistant prostate cancer: locking up the molecular escape routes. Clinical Cancer Research 15(10), 3251-3255 (2009)
40. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.Constitutively active androgen receptor splice variants expressed in castrationresistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America 107(39), 16759-16765. (2010)
41. DeVere White RW, Vinall RL, Tepper CG, Shi XB. MicroRNAs and their potential for translation in prostate cancer. Urol Oncol 27(3), 307-11 (2009)
42. Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn F, Hackermüller J. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene (Epub ahead of print) (2012)
43. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14(3), 417-24 (2008) (Pubitemid 351397806)
44. Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 25(4), 1198-207 (2011)
45. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101, 2999-3004 (2004) (Pubitemid 38327724)
46. Ozen M, Creighton C, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27, 1788-1793 (2007)
47. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucl Acids Res 33, 5394-5403 (2005) (Pubitemid 41548806)
48. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes & Development 21, 1025-1030 (2007) (Pubitemid 46686471)
49. Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R. RAS is regulated by the let-7 microRNA family Cell 120, 635-647 (2005) (Pubitemid 40343076)
50. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39, 673-677. (2007) (Pubitemid 46676103)
51. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem 287(2), 1527-37. (2012)
52. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One 7(3), e32832 (2012)
53. E. D. Crawford, M. A. Eisenberger, D. G. McLeod et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 321(7), 419-424. (1989) (Pubitemid 19211484)
54. M. A. Eisenberger, B. A. Blumenstein, E. D. Crawford et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New England Journal of Medicine 339(15), 1036-1042 (1998) (Pubitemid 28457865)
55. Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. PLoS One 6(11), e27178. (2011)
56. Lehmusvaara S, Erkkilä T, Urbanucci A, Jalava S, Seppälä J, Kaipia A, Kujala P, Lähdesmäki H, Tammela TL, Visakorpi T. Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate. Prostate (Epub ahead of print) (2012)
57. R. Kulshreshtha, M. Ferracin, S.E. Wojcik. A microRNA signature of hypoxia. Mol Cell Biol 27,1859-1867. (2007)
58. C. Camps, F.M. Buffa, S. Colella. Hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14, 1340-1348. (2008) (Pubitemid 351413913)
59. A. Giannakakis, R. Sandaltzopoulos, J. Greshock. MiR- 210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 7, 255-264. (2008) (Pubitemid 351590433)
60. Quero L, Dubois L, Lieuwes NG, Hennequin C, Lambin P. miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother Oncol 101(1), 203-8. (2011)
61. Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH, Chen LM, Hsieh CJ, Huang SP. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res 17(4), 928-36 (2011)